Pharmacogenomics and Personalized Medicine

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open access journal published by Dove Medical Press, devoted to how inherited variation shapes drug response and to the individualized prescribing that follows from it. Launched in 2008, it recorded a 2025 Journal Impact Factor of 2.4 and ranks in the third quartile of the pharmacology and pharmacy category.《药物基因组学与个体化医疗》是一份由 Dove Medical Press 出版的国际同行评审开放获取期刊，关注遗传变异如何影响药物反应，以及由此形成的个体化处方路径。该刊创办于 2008 年，2025 年期刊影响因子为 2.4，在药理学与药学类目位列第三四分位。

Scope

• The core subject is the influence of inherited variation on drug handling, from polymorphisms in cytochrome P450 enzymes and drug transporters to variants that shift receptor sensitivity.核心议题是遗传变异对药物处置的影响，范围从细胞色素 P450 酶与药物转运体的多态性，到改变受体敏感性的变异。
• Individualized drug selection and dose adjustment form the applied end of that programme, with genotype-guided prescribing presented as a route to better safety, efficacy and durability of treatment.个体化选药与剂量调整构成这一取向的应用端，基因导向的处方被视为通向更好安全性、疗效与治疗持续性的路径。
• Oncology occupies a large share, covering somatic markers that direct targeted agents, germline variants linked to the toxicity of cytotoxic drugs, and the pharmacogenomics of supportive care.肿瘤领域占很大篇幅，涉及指导靶向药物的体细胞标志物、与细胞毒药物毒性相关的胚系变异，也涉及支持治疗中的药物基因组学。
• Cardiovascular prescribing supplies a second cluster, with clopidogrel response and warfarin dose prediction among the cases where genotype has already entered clinical guidance.心血管用药构成第二个板块，氯吡格雷反应与华法林剂量预测属于基因信息已经进入临床指南的情形。
• Psychiatry and neurology appear through antidepressant and antipsychotic metabolism, hypersensitivity alleles for antiepileptic drugs, and the interpretation of combinatorial pharmacogenomic reports.精神科与神经科的内容通过抗抑郁药和抗精神病药的代谢、抗癫痫药的超敏等位基因，以及组合式药物基因组学报告的解释进入刊物。
• Infectious disease papers examine host genetics in tuberculosis and HIV therapy, hypersensitivity to antiretroviral agents, and the interplay between pathogen genotype and antimicrobial choice.感染病领域的论文考察结核与 HIV 治疗中的宿主遗传学、对抗逆转录病毒药物的超敏反应，也考察病原体基因型与抗菌药物选择之间的相互作用。
• Transplant and immunology work centres on therapeutic drug monitoring for tacrolimus and on thiopurine methyltransferase genotyping before azathioprine, two tests that already belong to routine care.移植与免疫学方面的研究集中在他克莫司的治疗药物监测，以及硫唑嘌呤使用前的硫嘌呤甲基转移酶基因分型，这两项检测都已进入常规诊疗。
• Paediatric dosing, pregnancy and renal or hepatic impairment receive attention, because the relation between genotype and exposure shifts when clearance is immature or compromised.儿科给药、妊娠以及肝肾功能受损的情形受到关注，清除能力尚未成熟或已经受损时，基因型与暴露量之间的关系会随之改变。
• Expression signatures, pharmacoepigenetic marks and circulating biomarkers stretch the scope beyond inherited DNA variation toward dynamic predictors of response.表达特征、药物表观遗传标记与循环生物标志物把收稿范围扩展到遗传性 DNA 变异之外，指向动态的反应预测因子。
• Implementation science runs through the title, from pre-emptive panel testing and clinical decision support alerts to the workflow changes that decide whether a test is used at all.实施科学贯穿整本刊物，从预先开展的组合检测与临床决策支持提示，到决定检测能否真正被使用的流程改造。
• Cohort studies, registry analyses and biobank-linked work supply real-world evidence on how often genotype-guided prescribing alters an outcome outside trial conditions.队列研究、登记数据分析与生物样本库关联研究提供真实世界证据，说明基因导向处方在试验条件之外改变结局的频率。
• Cost-effectiveness modelling, budget impact and equity of access are treated as part of the case for testing rather than as an afterthought.成本效果建模、预算影响与可及性公平被视为检测论证的组成部分，并未被当作事后补上的附加项。
• Regulatory approval of biomarker-defined indications, protection of genomic data and the handling of incidental findings fall inside the remit as well.以生物标志物界定的适应症如何获得监管批准、基因组数据的保护以及偶然发现的处理，同样在收稿范围之内。
• Methodological papers address variant annotation, polygenic scores, phenotyping from electronic records and the statistical power that pharmacogenomic association studies seldom have.方法学论文讨论变异注释、多基因评分、基于电子病历的表型界定，以及药物基因组关联研究往往欠缺的统计功效。
• Durability of response and antimicrobial stewardship give the word sustainability in the journal's statement a practical meaning, since resistance and loss of efficacy are themselves genotype-dependent.反应持续时间与抗菌药物管理让刊物宗旨里的「可持续性」具备实际含义，耐药与疗效丧失本身就与基因型相关。

History

• Dove Medical Press opened the title in 2008 from its Auckland base, and volume 1 carried just two papers, a scale that says much about how small the field then was.Dove Medical Press 于 2008 年在奥克兰推出该刊，第 1 卷只刊登两篇论文，这一规模大致反映出当时该领域的体量。
• No print edition has ever been issued. The journal carries the electronic ISSN 1178-7066 alone, a pattern common across the publisher's list.该刊从未发行印刷版，只使用电子国际标准刊号 1178-7066，这也是该出版方刊群的常见做法。
• One volume has appeared in each calendar year since launch, so volume 1 covers 2008 and volume 19 covers 2026, with no issue numbers dividing the annual volume.自创刊起每个日历年出版一卷，第 1 卷对应 2008 年，第 19 卷对应 2026 年，卷内不再划分期号。
• Articles are posted once proofs are cleared rather than held back for an issue, which is why the contents of any volume mix dates from across the year.论文在校样确认后即上线，并不等待凑齐一期，因此同一卷的目录会混排全年不同月份的文章。
• The National Library of Medicine indexes it as "Pharmacogenomics and personalized medicine", abbreviates the title to "Pharmgenomics Pers Med", and traces coverage to volume 1 in 2008.美国国家医学图书馆将其著录为「Pharmacogenomics and personalized medicine」，缩写取「Pharmgenomics Pers Med」，收录可追溯到 2008 年第 1 卷。
• Full texts are deposited in PubMed Central, so the archive can be read without a subscription and the earliest volumes remain as open as the current one.全文同时存入 PubMed Central，读者无需订阅即可阅读，最早各卷与最新一卷同样开放。
• Output climbed through the 2010s and reached 155 papers in 2021, the highest annual total on record, before falling to 82 in 2022 and rising to 97 in 2023.发文量在 2010 年代持续攀升，2021 年达到 155 篇，为该刊历史最高年度总量，2022 年回落至 82 篇，2023 年又升至 97 篇。
• The count dropped to 44 papers in 2024 and 23 in 2025, while 2026 has brought 20 so far, taking the cumulative total to 708 articles across nineteen volumes.2024 年降至 44 篇，2025 年为 23 篇，2026 年迄今已有 20 篇，十九卷累计刊出 708 篇论文。
• In 2023 Dove Medical Press became part of Taylor & Francis Group, the academic publishing division of Informa, and the footer of the journal page now states the relationship verbatim.2023 年 Dove Medical Press 并入 Informa 旗下的学术出版部门 Taylor & Francis 集团，刊页页脚如今以原话注明这一归属关系。
• The acquisition left the imprint, the title and the volume numbering in place, so citations written before 2023 still resolve to the same journal.收购之后品牌、刊名与卷号体系均保持原样，2023 年之前写下的引文仍指向同一份刊物。
• Clarivate recorded a Journal Impact Factor of 2.606 for 2022, then 1.8 in both 2023 and 2024, before the 2025 figure returned to 2.4 with a five-year value of 2.2.Clarivate 记录的期刊影响因子 2022 年为 2.606，2023 年与 2024 年均为 1.8，2025 年回升至 2.4，五年期数值为 2.2。
• The 2025 Journal Citation Reports place the title 215th of 356 in pharmacology and pharmacy, with a Journal Citation Indicator of 0.54 and a percentile of 39.7.2025 年期刊引证报告把该刊排在药理学与药学类目的 215/356 位，期刊引证指标为 0.54，百分位为 39.7。
• Total citations in the same report reach 1,415 against an annual output of 18 papers, and a cited half-life of 4.6 years is moderate for a title of this size.同一份报告记录的总被引次数为 1415，年发文 18 篇，4.6 年的引用半衰期对这样规模的刊物属于中等水平。
• Gold open access accounts for 98.73 per cent of the content, with papers issued under CC BY or CC BY-NC licences according to the choice made by their authors.金色开放获取占全部内容的 98.73%，论文按作者的选择以 CC BY 或 CC BY-NC 许可发布。
• The Directory of Open Access Journals has listed the title since its launch year, and the record has stayed in place without a break.开放获取期刊目录自创刊当年即收录该刊，条目此后一直保留。
• No renaming has occurred, so no former title has to be traced when the backfile is cited, and the volume sequence that began in 2008 runs unbroken.该刊从未更名，引用过刊时无需追溯旧题名，2008 年起始的卷号一路连续。

Editors

• Martin H. Bluth holds the editor-in-chief position, dividing his time between the pathology department of Wayne State University School of Medicine and Maimonides Medical Center in New York.主编由（Martin H. Bluth）担任，其工作横跨韦恩州立大学医学院病理学系与纽约的迈蒙尼德医疗中心。
• At Maimonides he directs transfusion medicine and donor services as well as translational research, posts that keep a hospital laboratory perspective inside the journal.在迈蒙尼德医疗中心，他主管输血医学与供者服务，同时负责转化研究，这些职务把医院实验室的视角带进刊物。
• He earned his MD and PhD at SUNY Downstate, where the doctorate was in immunology, and his bibliography now runs past 250 papers.他在纽约州立大学下州医学中心取得医学博士与博士学位，博士阶段研究免疫学，发表论文已超过 250 篇。
• The editorial board lists 11 members, six of them in the United States, two in Australia, and one each in Germany, Japan and the Netherlands.编委会列出 11 位成员，其中美国 6 位、澳大利亚 2 位，德国、日本与荷兰各 1 位。
• Hiltrud Brauch, deputy director of the Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, brings a long record in the pharmacogenetics of drug-metabolizing enzymes.（Hiltrud Brauch）是德国 Dr. Margarete Fischer-Bosch 临床药理研究所副所长，为编委会带来药物代谢酶药物遗传学方面的长期积累。
• Kimberly Compton, professor of life sciences at Arizona State University, also holds adjunct appointments at the Mayo Clinic and at Johns Hopkins.（Kimberly Compton）为亚利桑那州立大学生命科学教授，同时在梅奥诊所与约翰斯·霍普金斯大学兼任教职。
• Vicki Ellingrod, at the University of Michigan College of Pharmacy, and Takahisa Furuta, at the Furuta Internal Medicine Clinic in Japan, cover clinical pharmacy and community gastroenterology.（Vicki Ellingrod）任职于密歇根大学药学院，（Takahisa Furuta）在日本 Furuta 内科诊所执业，两人分别覆盖临床药学与社区消化科。
• Jing Li, at the Karmanos Cancer Institute and Wayne State University, and Senthil Lingaratnam, head of pharmacy at Peter MacCallum Cancer Centre in Melbourne, represent the oncology side.（Jing Li）任职于卡马诺斯癌症研究所与韦恩州立大学，（Senthil Lingaratnam）任墨尔本彼得·麦卡勒姆癌症中心药学部主任，两人代表肿瘤学方向。
• Two members sit at the University at Buffalo, Qing Ma in the School of Pharmacy and Gene Morse, a SUNY Distinguished Professor who works on antiretroviral and antituberculosis drugs.两位成员任职于布法罗大学，（Qing Ma）在药学院，（Gene Morse）为纽约州立大学杰出教授，研究抗逆转录病毒与抗结核药物。
• Anke-Hilse Maitland-van der Zee holds the chair in precision medicine in respiratory disease at Amsterdam UMC, which puts inhaled and biologic therapy for asthma within the board's view.（Anke-Hilse Maitland-van der Zee）在阿姆斯特丹大学医学中心担任呼吸系统疾病精准医学教授，使哮喘的吸入治疗与生物制剂治疗进入编委会视野。
• Wolfgang Sadee, emeritus at Ohio State University and at the University of California, San Francisco, and Andrew Somogyi, professor of clinical and experimental pharmacology at Adelaide, bring expertise in transporter and opioid pharmacology.（Wolfgang Sadee）为俄亥俄州立大学与加州大学旧金山分校荣休教授，（Andrew Somogyi）是阿德莱德大学临床与实验药理学教授，两人分别带来转运体药理学与阿片类药物药理学的专长。
• Every manuscript passes through single anonymous peer review, in which referees stay unknown to the authors while author identities remain visible to them.所有稿件都经过单盲同行评审，审稿人对作者匿名，作者身份对审稿人可见。
• The imprint belongs to the Committee on Publication Ethics and sends each submission through Crossref Similarity Check before a referee sees it.该出版方是出版伦理委员会成员，每篇来稿在送交审稿人之前先经 Crossref Similarity Check 查重。
• Publication costs rest on authors rather than subscribers, and the publisher grants full waivers to low-income countries and half waivers to lower-middle-income ones.出版费用由作者承担而非订阅机构，出版方对低收入国家作者全额减免，对中低收入国家作者减半收取。